The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Sheba Medical Center, Tel Hashomer
Ramat Gan, Tel Aviv, Israel
RECRUITINGClinical deterioration
Patients chance of clinical deterioration of COVID19 disease as defined by percentage of patients requiring oxygen therapy during their hospitalization.
Time frame: 14 days
Changes in NEWS scale
NEWS2- National Early Warning Score - a score defining the probability of severe COVID 19 disease. Minimum score is 0, while maximum score is 23. Higher score means worse outcome
Time frame: 14 days
Supportive care therapies
Percentage of patients requiring the respiratory support of either of the following : high flow nasal canula oxygen support, mechanical ventilation or use of extra corporeal membrane oxygenation.
Time frame: 14 days
SARS-COV2 presence
Presence of SARS-COV2 in oral \& nasal secretions in days 10, 14 of the study
Time frame: 10 days, 14 days
Hospitalization Days
Hospitalization days due to COVID-19
Time frame: 14 days
Cytokine Levels
IL2, IL18, IL8. IL6, IL10, TNF-alpha, TGF-beta levels at day 3, day 7 and discharge day (which is on average the 10th day of hospitalization). All cytokine levels would be measured by pg/mL.
Time frame: Day 3, day 7, discharge day (which is on average the 10th day of hospitalization).
Hamilton Anxiety Score
A verified score measuring anxiety. Minimum score is 0, while maximum score is 56. Higher scores mean worse outcome.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 14 days